Bausch + Lomb Corporation (NYSE/TSX: BLCO), a global leader in eye health, announced today the acquisition of Elios Vision, Inc., the developer of the ELIOS™ procedure—an innovative, clinically validated, minimally invasive glaucoma surgery (MIGS) technique utilizing an excimer laser. This acquisition significantly enhances Bausch + Lomb’s glaucoma treatment offerings and creates new opportunities for addressing glaucoma in conjunction with cataract surgery, without the need for implants.
Luc Bonnefoy, President of Bausch + Lomb’s Surgical division, emphasized the strategic importance of the acquisition, stating, “Today’s announcement further demonstrates our commitment to investing in smart, innovative technologies that enable eye care professionals to better address the evolving needs of their patients.” He highlighted the importance of the ELIOS system, especially as glaucoma is projected to affect a growing number of individuals, with prevalence expected to rise by 47% between 2020 and 2040.
MIGS procedures, such as ELIOS, offer a safer and more effective means of lowering intraocular pressure with faster recovery times compared to traditional glaucoma surgeries. The procedure can be performed in tandem with cataract surgery, the most commonly performed procedure worldwide. With over 19% of cataract surgery patients also affected by glaucoma or ocular hypertension, combining the two treatments offers an efficient and optimal approach.
Professor Ike K. Ahmed, MD, from the University of Toronto and Moran Eye Center, praised the ELIOS system for its precision and tissue-friendly, non-thermal laser technology. “The synergy between cataract surgery and MIGS can help ophthalmologists provide streamlined care and improve patient quality of life,” he stated.
The acquisition of Elios Vision aligns with Bausch + Lomb’s global reach in cataract surgery, expanding the availability of ELIOS to a broader network of eye care professionals. Elliot Friedman, former Chairman and CEO of Elios Vision, emphasized that Bausch + Lomb’s presence in nearly 100 countries will help establish the combined cataract and glaucoma treatment approach as the new standard of care for the estimated 80 million people worldwide living with glaucoma.
Currently CE marked, the ELIOS system is available in the European Union, while Elios Vision is working to secure U.S. Food and Drug Administration approval.
About Bausch + Lomb
Bausch + Lomb is dedicated to enhancing and preserving sight for people worldwide, offering a broad portfolio of approximately 400 products, including contact lenses, eye care products, pharmaceuticals, and surgical devices. With a presence in nearly 100 countries, Bausch + Lomb has been a leader in eye health for over 170 years.
About Elios Vision, Inc.
Elios Vision Inc. is a privately held company focused on advancing safe and effective glaucoma treatments to improve the lives of millions of patients affected by the condition.
Forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied in this release.
Related topic:
ODORBN Advocates for Stronger Eye Care Standards in Nigeria
Provectus Launches VisiRose to Tackle Eye Infections
Alcon Marks First Anniversary of African Phaco Program
